Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Apr;86(4):e107-e110.
doi: 10.1016/j.jinf.2023.02.007. Epub 2023 Feb 10.

Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors

Wan-Hsuan Hsu  1 , Ya-Wen Tsai  2 , Jheng-Yan Wu  3 , Ting-Hui Liu  1 , Chih-Cheng Lai  4
Affiliations
Comment

Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors

Wan-Hsuan Hsu et al. J Infect. 2023 Apr.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The algorithm of patient selection and cohort construction.
Fig. 2
Fig. 2
Kaplan-Meier time-to-event curves for patients receiving nirmatrelvir/ritonavir (NMV-r) versus patients not receiving NMV-r for the composite outcome of all-cause mortality or hospitalization.
Fig. 3
Fig. 3
Kaplan-Meier time to event curves for patients receiving nirmatrelvir/ritonavir (NMV-r) versus patients not receiving NMV-r for the outcomes of the probabilities of (a) all-cause mortality, (b) hospitalization, and (c) critical care service use.
See this image and copyright information in PMC

Comment on

References

    1. Gentry C.A., Nguyen P., Thind S.K., Kurdgelashvili G., Williams R.J. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents. J Infect. 2023 doi: 10.1016/j.jinf.2023.01.018. - DOI - PMC - PubMed
    1. Zheng Q., Ma P., Wang M., Cheng Y., Zhou M., Ye L., et al. Efficacy and safety of Paxlovid for COVID-19:a meta-analysis. J Infect. 2023;86(1):66–117. - PMC - PubMed
    1. Liu T.H., Wu J.Y., Huang P.Y., Tsai Y.W., Lai C.C. The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: a retrospective cohort study including 91,528 patients. J Infect. 2023 - PMC - PubMed
    1. Xie Y., Choi T, Al-Aly Z. Nirmatrelvir and the risk of post-acute sequelae of COVID-19; 2022. doi: 10.1101/2022.11.03.22281783. - DOI
    1. https://trinetx.com/ (Accessed January 31, 2023).